The safety of supported psilocybin use in Oregon
Nat Med
.
2024 Jan;30(1):17-18.
doi: 10.1038/s41591-023-02727-4.
Authors
William R Smith
1
2
,
Dominic A Sisti
3
,
Paul S Appelbaum
4
5
Affiliations
1
Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. william.smith@pennmedicine.upenn.edu.
2
Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA. william.smith@pennmedicine.upenn.edu.
3
Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
4
Department of Psychiatry, Columbia University, Vagelos College of Physicians & Surgeons, New York, NY, USA.
5
Center for Law, Ethics & Psychiatry, New York State Psychiatric Institute, New York, NY, USA.
PMID:
38238619
DOI:
10.1038/s41591-023-02727-4
No abstract available
Publication types
Letter
MeSH terms
Hallucinogens*
Oregon
Psilocybin* / adverse effects
Substances
Psilocybin
Hallucinogens
Grants and funding
T32MH019112/U.S. Department of Health ; Human Services | NIH | National Institute of Mental Health (NIMH)